Anorexia: a taste of things to come?
Anorexia, the loss of the desire to eat, is common in patients with cancer. Studies report a prevalence of up to 66% and clinical practice suggests that it is an almost universal experience as the cancer progresses. It generally leads to a reduction in food intake that contributes to the development of malnutrition and cachexia, impairing quality of life and increasing morbidity and mortality. Successful curative or palliative treatment of the underlying cancer is an effective approach. When this is not possible, there are limited treatment options, which generally have not been shown to be practicable, tolerable, effective or safe in the long-term management of the cachexia-anorexia syndrome. Recent increases in the understanding of the physiology of energy intake and of the pathophysiology of anorexia are helping to guide the development of rational approaches. This journal club provides an outline of the pathophysiology of anorexia and highlights a paper that may provide an exciting glimpse of the future.
Wilcock
Andrew
A
University of Nottingham, Hayward House Macmillan Palliative Care Cancer Unit, Nottingham City Hospital NHS Trust, UK. andrew.wilcock@nottingham.ac.uk
D000818:Animals; D000855:Anorexia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D002100:Cachexia / Q000209:etiology; D016207:Cytokines / Q000378:metabolism; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000150:complications; D044105:Receptor, Melanocortin, Type 4 / Q000037:antagonists & inhibitors*
D016207:Cytokines; D044105:Receptor, Melanocortin, Type 4